Tolerability and safety of the intravenous immunoglobulin octagam^® 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials

References

• Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24–33. Epub 2013/05/25. doi: 10.1007/s12185-013-1370-4
   PubMed Web of Science ®Google Scholar
• Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost. 2012;10:1988–1998. Epub 2012/08/07. doi: 10.1111/j.1538-7836.2012.04876.x
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–4207. Epub 2011/02/18. doi: 10.1182/blood-2010-08-302984
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–186. Epub 2009/10/23. doi: 10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Octapharma Ltd. Octagam 10% solution for infusion: summary of product characteristics [Internet]. 2016 Apr 12 [cited 2016 Oct 3]. Available from: https://www.medicines.org.uk/emc/medicine/24831
   Google Scholar
• Octapharma USA Inc. Octagam 10% [immune globulin intravenous (human)] liquid solution for intravenous administration: US prescribing information [Internet]. 2014 Jul [cited 2016 Oct 3]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm064946.pdf
   Google Scholar
• Frenzel W, Wietek S, Svae TE, et al. Tolerability and safety of octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016;54:847–855. Epub 2016/10/11. doi: 10.5414/CP202782
   PubMed Web of Science ®Google Scholar
• Robak T, Mainau C, Pyringer B, et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (Octagam® 10%) in patients with immune thrombocytopenia. Hematology. 2010;15:351–359. Epub 2010/09/25. doi: 10.1179/102453310X12719010991867
   PubMed Web of Science ®Google Scholar
• Blažek B, Misbah SA, Soler-Palacin P, et al. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study. Immunotherapy. 2015;7:753–763. Epub 2015/04/14. doi: 10.2217/imt.15.30
   PubMed Web of Science ®Google Scholar
• Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004;91:771–778. Epub 2004/03/27.
   PubMed Web of Science ®Google Scholar
• Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14:227–236. Epub 2009/07/29. doi: 10.1179/102453309X439773
   PubMed Web of Science ®Google Scholar
• Dash CH, Gillanders KR, Stratford Bobbitt ME, et al. Safety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075). PLoS One. 2014;9:e96600. Epub 2014/06/04. doi: 10.1371/journal.pone.0096600
   PubMed Web of Science ®Google Scholar
• Julia A. The experience of Flebogammadif® in primary immune thrombocytopenia. Clin Exp Immunol. 2011;164(Suppl 2):12–15. Epub 2011/04/16. doi: 10.1111/j.1365-2249.2011.04389.x
   PubMed Web of Science ®Google Scholar
• van der Meer JW, van Beem RT, Robak T, et al. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sang. 2011;101:138–146. Epub 2011/07/14. doi: 10.1111/j.1423-0410.2011.01476.x
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171–178. Epub 2013/07/10. doi: 10.1016/j.tmrv.2013.05.004
   PubMed Web of Science ®Google Scholar
• Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf. 2007;16:1038–1047. Epub 2007/07/20. doi: 10.1002/pds.1449
   PubMed Web of Science ®Google Scholar
• Sridhar G, Ekezue BF, Izurieta HS, et al. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Transfusion. 2014;54:2553–2565. Epub 2014/05/09. doi: 10.1111/trf.12663
   PubMed Web of Science ®Google Scholar
• Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf. 2010;9:971–979. Epub 2010/04/23. doi: 10.1517/14740338.2010.484419
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–542. Epub 2006/03/01. doi: 10.1016/j.intimp.2005.11.015
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) [Internet]. 2010 Oct 21 [cited 2015 Oct 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/12/WC500099542.pdf
   Google Scholar
• Dhainaut F, Guillaumat PO, Dib H, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104:115–126. Epub 2012/09/26. doi: 10.1111/j.1423-0410.2012.01648.x
   PubMed Web of Science ®Google Scholar
• Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25:78S-84S. Epub 2005/10/19. doi: 10.1592/phco.2005.25.11part2.78S
   PubMed Web of Science ®Google Scholar
• Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med. 2010;122:176–184. Epub 2010/09/24. doi: 10.3810/pgm.2010.09.2214
   PubMed Web of Science ®Google Scholar
• Etscheid M, Breitner-Ruddock S, Gross S, et al. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang. 2012;102:40–46. Epub 2011/05/07. doi: 10.1111/j.1423-0410.2011.01502.x
   PubMed Web of Science ®Google Scholar
• Germishuizen WA, Gyure DC, Stubbings D, et al. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals. 2014;42:260–270. Epub 2014/08/07. doi: 10.1016/j.biologicals.2014.04.002
   PubMed Web of Science ®Google Scholar
• Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38:275–284. Epub 2013/09/21. doi: 10.1159/000354893
   PubMed Web of Science ®Google Scholar
• Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci. 2012;46:93–96. Epub 2011/12/16. doi: 10.1016/j.transci.2011.11.004
   PubMed Web of Science ®Google Scholar